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Background: Implantation of Drug Eluting Stents (DES) plus bioresorbable scaffolds (BVS) in very long diffuse left
anterior descending coronary artery (LAD) disease may be problematic because of multiple devices overlapping.
We sought to assess the short and mid-tern outcomes of combined implantation of DES and BVS using a novel
“edge-to-edge” technique in patients with diffuse LAD disease.
Methods: Patients with long diffuse LAD disease were enrolled in a prospective registry from 1st August 2014 to 1st
August 2015 and treated with IVUS-aided percutaneous coronary intervention using aDES plus a single or multiple
BVS using a novel “edge-to-edge” technique. Clinical follow up and invasive follow up driven by clinical
justiﬁcation was performed.
Results: Twenty-three patients (5 females, mean age 59.1 9.1 years) were enrolled. Mean length of LAD disease
was 73.1 20.6mm. Mean number of DES and BVS implanted was 1.2 0.4 and 1.7 1.3, respectively. At a mean
follow-up of 11.3 3.8 months, no stent thrombosis or MACE were observed. Angiographic and IVUS follow-up at
a mean of 6.6 0.7 months showed no signiﬁcant angiographic restenosis and no appreciable stent gaps.
Conclusions: In revascularization of long diffuse disease of the LAD, the edge-to-edge implantation technique
appears to be feasible resulting in no restenosis or thrombosis on the short-term follow-up. (J Interven Cardiol
2016;29:275–284)
Introduction
Current-generation drug-eluting stents (DES) hold
several advantages over ﬁrst generation DES and bare
metal stents.1 Permanent metallic stenting of the
coronary vessel is perceived as a limitation, because it
abrogates vasomotion, thereby preventing late
expansive remodeling. Bioresorbable scaffolds, and
in particular the everolimus-eluting Absorb Bioresorb-
able Vascular Scaffold (BVS) (Abbott Vascular, Santa
Clara, CA, USA), promise complete bioresorption
after two to three years, vessel lumen enlargement,
reduction of the plaque-media ratio, and restoration of
vasomotion.2,3 These characteristics may be particu-
larly appealing when faced with very long, diffuse
disease of main vessels unsuitable for surgery, such as
the Left Anterior Descending coronary artery (LAD).
In the real world a long LAD lesion is very often
associated with disease of the proximal LAD bifurca-
tion and some reports suggest the use of a hybrid
strategy consisting of implanting a regular DES in the
LAD-ﬁrst Diagonal (D1) site and treating the rest of
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the disease with a BVS.4,5 Third-generation DES seem
to offer very promising outcomes in simple and
complex bifurcation lesions approached with a single
or even double stent technique.6,7 Multiple BVS
implantation has been suggested anecdotally to be
safe and effective.8,9
Outcomes of such a hybrid strategy have not yet
been reported in a case series, nor has the impact of
multiple BVS implantation and the ideal overlapping
technique amongst BVS devices and between DES and
BVS in such an anatomic picture (1mm, or less, or no
overlapping at all). We sought to assess the short and
mid-tern outcomes of a hybrid revascularization
strategy consisting of the combined implantation of
DES at the LAD-D site and BVS at the mid and distal
LAD with a minimal or no –overlapping (edge-to-
edge) technique in patients with diffuse LAD disease
not suitable for surgery, in a prospective registry at two
sites in Italy, the Rovigo General Hospital, Rovigo and
the Mestre General Hospital, Mestre-Venice.
Methods
Patients with long diffuse signiﬁcant disease of the
left anterior descending coronary artery which were
not suitable for surgery on the basis of disease
extension on coronary artery angiography were
enrolled in a prospective registry from 1st August 2014
to 1stAugust 2015.
Clinical (cardiovascular risk factors, Canadian Car-
diovascular Score class, EUROSCORE10) and angio-
graphic characteristics (lesion/s location and severity
according to the SYNTAX score11 and MEDINA
classiﬁcation12) were analyzed by a Heart Team
composed of the referral cardiac surgeon, the referral
clinical cardiologist and the interventional cardiologist.
Exclusion criteria included: ST-elevation acute
coronary syndrome with LAD as the infarcted artery,
diameter of the proximal LAD>4mm and of the mid-
distal portion <2.25mm after nitroglycerin intra-
coronary injection (200 micrograms), severe calciﬁca-
tion of the mid-distal portions of the LAD not
amenable to adequate lesion preparation, age >70
years old, clinical comorbidities causing inability to
maintain double antiplatelet regimen for 12 months
and life-expectance <2 years.
Patients not suitable for surgery underwent a
percutaneous coronary intervention according to the
current guidelines13 using a drug eluting stent (Promus
Premier, Boston Scientiﬁc, Galway, Ireland) at the
LAD-D bifurcation (distal left main shaft stenosis was
not considered an exclusion criteria) plus a single or
multiple BVS (Absorb, Abbot Vascular, Santa Clara,
CA, USA) for the mid (LAD II) and distal portion of
the LAD (LAD III). Additional signiﬁcant lesions in
other vessels were treated with staged procedures and a
routine DES of the operator’s choice (Promus Premier,
Boston Scientiﬁc, Galway, Ireland; Orsiro, Biotronik,
Bulack, Switzerland; Resolute Integrity, Medtronic
Inc., Galway, Ireland). All patients signed the
informed consent and the Hospital Editorial Board
approved the study.
During PCI, patients were anticoagulated with
unfractionated heparin (a bolus of 40U/ kg and
additional heparin to achieve an activated clotting
time of 250–300 seconds). All patients were advised to
maintain the use of aspirin lifelong. Twelve-month
Prasugrel or Ticagrelor treatment was recommended.
PCI Protocol. Steps included:
1) Coronary angiography with intracoronary nitro-
glycerin injection through a 6F femoral guiding
catheter or through a 6 F right or left radial
approach.
2) Intravascular ultrasound evaluation of the LAD
diameter and lesion length: pre-dilation using
non- compliant balloons (Sprinter NC or Eu-
phora, Medtronic, USA). The size was chosen on
the basis of IVUS ﬁndings with 1:1 ratio at
nominal atmospheres (atm) with increasing
pressure until the rated burst pressure was
reached or until the residual stenosis by QCA
was less than 10%.
3) BVS size and length was chosen on the basis of
IVUS ﬁndings following the company charts
(2.25–2.5mm, 2.5mm device; 2.5–3.0mm,
3.0mm device; 3.0–3.5mm, 3.5mm device).
- Minimal or no overlapping among BVS in
the mid-distal portions of the LAD and
between BVS and DES at the proximal LAD
in order to prevent excessive strut protrusion
within the vessel lumen.
- DES at the LAD-D site was implanted
following a standard protocol, as suggested
by the European Bifurcation Club
recommendations.14
- Post dilation of BVS with non-compliant
balloons not exceeding 0.5mm of the
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scaffold diameter at 20 atm. Post-dilation of
DES at 20 atm with non-compliant balloons
of diameter up to 1.5mm exceeding the stent
diameter.
- Control IVUS: eventual additional post-
dilation at increasing pressure till the RBP
was reached or until a residual stenosis of
<10% was obtained or strut malapposition
on IVUS was noticed.
Overlapping Technique. Choice of implanting
the DES as the ﬁrst step or the ﬁnal step after BVS
implantation was left to the operator’s discretion on the
basis of the LAD-D complexity on coronary angiog-
raphy. Attention was required by the operators in order
to leave minimal or no overlapping (edge-to-edge
technique) between BVS and DES and among each
BVS implanted.
In developing an ad hoc overlapping strategy, we
considered some main concepts:
Firstly, it would be easier to position the BVS with
the aid of the radio-opaque BVS balloon markers for
overlapping of the ﬁxed DES. Secondly, the BVS
would lie on top of the metallic stent at the overlapped
junction and would not cause any metallic strut
disruption once the temporary scaffold was fully
resorbed.
If the BVS was positioned ﬁrst distally and then
overlapped proximally with a DES, the thinner
metallic struts would lie on top of the thicker BVS
scaffold at the overlapped junction. Once the BVS
scaffold beneath the metallic strut has resorbed, this
would leave a segment of overhanging metallic strut
which would not be apposed to the vessel wall. The
longer the overlapping segment, the longer the length
of potentially malapposed stent segment. The expan-
sive remodeling property of the BVS may also
contribute to the malapposition phenomenon at the
DES–BVS overlap junction.
The current BVS has thicker struts and a larger
crossing proﬁle. From our experience with BVS
implantation, we believe that crossing an already fully
expanded DES can be very difﬁcult and could damage
the BVS struts, lengthening the procedural time and
increasing the risk of complications.
To overcome all these issues, we employed a
minimal (less than 1mm) or no overlapping (edge-to-
edge technique) slightly different form the standard
technique (Fig. 1):
1) Between two BVS: for scaffolds of any size the
balloon of the implanting device was lined up not
with the deployed scaffold marker beads, which
should result in a 1mm overlapping, but at the
edge of the deployed scaffold marker beads,
which should result in less than 1mm or no
overlapping;
2) Between the DES and the BVS:
a) The balloon marker of the implanting DES
was lined up with the second marker beads
of the deployed scaffold in scaffolds
3.5mm, in whom the marker is placed
1.4mm inside from the outer edge proxi-
mally, which should result in less than
1mm or no overlapping.
b) The balloon of the implanting DES was
lined up with the edge of the deployed
scaffold marker beads in scaffolds
2.5–3.0mm, in whom the marker is placed
1.1mm inside from the outer edge proxi-
mally, which should result in less than
1mm or no overlapping.
That obviously differs if another type of
DES than Promus Premier has to be used,
being the edge of the stent on the marker of
the balloon in other types of stent.
Angiographic Protocol. For device implantation
purposes, the LAD was divided in segments as
following:
- LAD-D: LAD proximalþ 10mm distally from
the ﬁrst diagonal branch with diameter >2mm.
- LAD II: 10mm distally to the ﬁrst diagonal branch
with diameter >2mm from the exit of the vessel
from the sulcus arteriosus.
- LAD III: from the exit from the sulcus to the apex.
Quantitative coronary angiographic (QCA) analysis
at baseline, post-stenting and at follow-up was
performed using edge detection techniques (CAAS
II 5.0 version; Pie Medical, Maastricht, Netherlands).
Minimal lumen diameter (MLD), reference vessel
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diameter (RVD), segment length, and diameter
stenosis ([1-MLD/RVD]  100) were assessed.
Binary restenosis was deﬁned as stenosis 50% of
the luminal diameter in the target lesion.
IVUS Protocol. Intravascular Ultrasound exami-
nation was performed using the 3 F Opticross coronary
IVUS catheter (Boston Scientiﬁc, Fremont, CA, USA)
and automatic pull-back system (0.5mm/s). On-line
ultrasound assessment was performed in diastole.
IVUS images were recorded after administration of
100–200mg of nitroglycerin. The ultrasound catheter
was advanced 0.5mm beyond the lesion/stent and was
pulled back to a point 0.5mm proximal to the lesion/
stent using motorized transducer pullback at 0.5mm/s
IVUS was performed and interpreted by the treating
physician and at least one experienced IVUS
technician.
The lumen cross sectional area (CSA) at the stent
level was assessed by planimetry at the interface of the
blood and the stent, at multiple levels (at least three),
and the smallest area was chosen. The proximal and
distal reference lumen areas and diameters were also
measured by manual planimetry. The reference
segments were selected as the most normal-looking
cross section within 10mm proximal and distal to the
stent. To reduce the variability, all IVUS measure-
ments were repeated, and the average of the two values
was used in the analysis. Routine measurements were
recorded pre- and post-stent implantation.15 On
follow-up IVUS control particular attention was carry
out in determining stent thrombosis or restenosis and in
evaluating the transition zone among DES and
scaffolds.
IVUS parameters at baseline, post stent, and on
eventual follow-up, were correlated to FFR to
verifying the lesion signiﬁcance16 and the achieved
results using the AVIO criteria.17
Deﬁnitions. Angiographic success was deﬁned as
a residual stenosis <30% by visual analysis in the
presence of Thrombolysis in Myocardial Infarction
(TIMI) 3 ﬂow grade.
Thrombosis was deﬁned as occurring within
24 hours of the procedure, subacute stent thrombosis
from 1 to 30 days, and late stent thrombosis beyond
30 days. Probable stent thrombosis included all
deﬁnite stent thrombosis, death of cardiac cause within
Figure 1. Schematic representation of the the standard technique (top of the ﬁgure) and the edge-to-edge overlapping technique in case of BVS/
BSV any size (top-middle), DES/BVS 2.5–3.0mm (middle-bottom), and DES/BVS 3.5mmm (bottom). On the right is represented the deployed
scaffold (red colour) whereas on the left is represented the undeployed device (BVS or DES, black colour). The vertical broken line represented
the point of lining up of devices.
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30 days of the index procedure, and Q-wave
myocardial infarction (MI) attributable to the target
vessel.
In-stent restenosis (ISR) was classiﬁed as focal
(<10mm long), diffuse (>10mm long), proliferative
(>10mm long and extending outside the stent edges),
or totally occluded.18
Major cardiac adverse event (MACE), including
death, Q-wave MI, and target vessel revascularization
(TVR). Death was all cause mortality. Cardiac death
included all deaths where a non-cardiac cause could
not be demonstrated. Q-wave MI was deﬁned as an
elevation in Troponin I level in the presence of new Q-
waves on the electrocardiograph in >2 contiguous
Leads, as measured at baseline and at 12 and 24 hours
and daily if increased 2X the baseline level, following
Thygesen K et al.19
Target lesion revascularization (TLR) was deﬁned
as revascularization, either percutaneous or surgical,
for a stenosis within stent or in the 5mm segments
proximal or distal to the stent. TVR was deﬁned as
either percutaneous or surgical revascularization of the
stented epicardial vessel.
Clinical Follow-Up. Per our institutional proto-
col, follow-up was conducted by physical examination
at 1, 6, 12 months and then yearly. Induced ischemia
test by means of Ergometric test, nuclear stress test or
stress echocardiography was scheduled at 6/8 months.
Transthoracic echocardiography was scheduled at
6 months. Angiographic and intravascular ultrasound
control was scheduled at 6/8 months, at the time of
additional vessel treatment or driven by clinical
symptoms or instrumental evidence of myocardial
ischemia. Information about in-hospital outcome was
obtained from an electronic clinical database for
patients maintained at our institution and by review of
hospital records for those discharged to referring
hospitals. Post-discharge survival status was obtained
from the Municipal Civil Registries. Information on
the occurrence of AMI or repeated interventions at
follow-up was collected by consulting our institutional
electronic database and by contacting referring
physicians and institutions and all living patients.
Results
Twenty-three patients (5 females, mean age
59.1 9.1 years), judged not to be candidates for
surgery, were enrolled (Table 1). Calciﬁcation was
apparent on angiography in the LAD-D segment in 22/
25 patients (86.9%) and at LAD II in 7/25 patients
(30.4%): no patients presented with calciﬁcation in the
LAD III, conﬁrming that the proposed strategy was
feasible.
As assessed by angiography, the mean treated
stenosis in LAD-D, LAD II, and LAD III were:
88.4 1.1, 85.4 3.7, and 87.6 5.6 %, respectively.
Percentage of Type C lesions was 89.9% (20/23),
69.5% (16/23), and 30.4 % (7/23) in LAD-D, LAD II,
and LAD III, respectively. Mean length of LAD
disease as assessed by IVUS was 73.1 20.6mm
(range 54–111mm).
Procedural Results. In all cases the DES has been
implanted at the last stent. Mean number of DES
implanted in the LAD-D was 1.2 0.4, whereas the
mean number of BVS was 1.7 1.3 for a mean length
of disease covered byDES andBVS of 30.9 12.8 and
Table 1. Demographical and Clinical Data
N° 23 (DS or %)






Valvular heart disease 3 (13)
EF (%) (SD) 40.2 5.6
CCS class (SD) 2.4 0.7
Transient ischemic attack/stroke 1 (4.3)
Heart failure 0 (0)
Severe COPD 3 (13)
Peripheral arterial disease 3 (13)
Carotid artery disease 1 (4.3)
Rest angina 5 (21.7)
Non-ST elevation ACS 14 (60.9)
ST-elevation ACS 4 (17.4)
1-vessel disease 9 (39.1)
2-vessel disease 8 (34.8)
3-vessel disease 6 (26.1)
Additional Left main disease (>50%) 1 (4.3)
LAD-D1 Medina classification 1,1,1 10 (43.5)
SINTAX score 20.3 7.2
ACS, acute coronary syndrome; CCS, Canadian Cardiovascular
Score; EF, ejection fraction calculated from left ventricle angiogra-
phy; SD, standard deviation.
Vol. 29, No. 3, 2016 Journal of Interventional Cardiology 279
DESþBVS FOR DIFFUSE LAD DISEASE
44.5 16.5, respectively (Fig. 2, Table 2). LAD-D
bifurcation was treated by single-stent strategy in 20/
23 patients (86.9%). Three patients required a double-
stent strategy (13.0%).
Four patients (17.4%) experienced an increase in
Troponin level 2 compared to the baseline value: three
patients had transient occlusion of the second Diagonal
and thirdDiagonal branches resolvedwith rewiring and a
2.0 15mm balloon dilation, whereas one patient
developed BVS mild thrombosis during implantation
of DES in a very lengthy procedure, resolved by a
glycoprotein IIb/IIIa inhibitor 8 hour-long infusion.
Unintentional overlapping between BVS and DES
and between BVSs <1mm was observed in 6/23
patients (26.1%): interestingly these patients were the
ﬁrst 6 patients treated with this strategy. At the start of
the study we tried to positioning the stent with regular
ﬂuoroscopy but the visualization of the marker was
suboptimal. In the subsequent cases we used angiogra-
phy with maximal image magniﬁcation which allowed
for an optimal visualization of the stent markers.
Clinical Follow-Up. Clinical follow-up was
available for 100% of patients. At a mean follow-up
of 11.3 3.8 months, no patient death, or MACE were
observed. A slightly improvement of EF on echocar-
diography compared to baseline (40.2 5.6 vs.
57.6 7.1 %, P< 0.01) and an improvement of CCS
(2.4 0.7 vs. 0.4 0.8, P< 0.01) were noticed.
Angiographic and IVUS Follow-Up. Angio-
graphic and IVUS follow-up was available for 15/23
patients (65.2%) at a mean of 6.6 0.7 months from
the index procedure. The remainder of the patients
were well with no symptoms or signs of reduced
coronary reserve by stress test. Reasons for an invasive
follow-up are detailed in Table 2.
No signiﬁcant angiographic restenosis of DES was
observed, whereas a moderate hyperlasia (<50%) of
BVS was diagnosed in 2/23 patients (8.7%) on
coronary angiography and conﬁrmed by IVUS: these
patients had unintentional overlapping on IVUS after
stent deployment at time of the ﬁrst procedure. They
were treated conservatively and continued with
clinical follow-up.
On IVUS, no appreciable gaps among BVS and
between the BVS and DES was noticed (Figs. 3 and 4),
No visible thrombus was noticed in any patients. Late
lumen loss for segment LAD-D, LAD II, and LAD III,
was 0.11 0.42mm, 0.12 0.47mm, 0.04 0.28mm,
respectively. A comparison of QCA and IVUS ﬁndings
at baseline, immediately after the indexprocedure and at
follow-up examination in patients with invasive follow-
up are summarized in Table 3.
Discussion
Our small pilot study of this very challenging
cohort of patients suggests that a hybrid revasculari-
zation strategy for the treatment of long, diffuse
disease of the LAD using DES plus single or multiple
Figure 2. Coronary angiography in a 51-year-old male (patient n°14) with non ST-elevation ACS involving LAD as the culprit lesion: (A)
Baseline Angiography Cranial AP view; (B) Edge-to-edge technique was used for stent overlapping: note the distance of the markers of the distal
and proximal BVS, slightly longer than usually suggested by the company (asterisk); (C) immediate post-procedural result after implantation of
2.5 28mm and 2.5 28mm Absorb plus a 3.5 26mm Promus Premier DES.
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BVS is feasible and relatively safe. Intriguingly, no
death, thrombosis or acute myocardial infarction or
TVR were experienced in a short-mid-term follow-up
by any of the patients, despite a high percentage of
multi-vessel disease treated. The edge-to-edge im-
plantation technique resulted in no signiﬁcant
restenosis or thrombosis as assessed by angiography
and IVUS examination in the patients with available
follow-up.
Surgical treatment of long, diffuse LAD disease is
still a matter of investigation. Sequential left internal
mammary artery (LIMA) implantation, although
feasible with good outcomes, is limited by the number
of segments to be treated (usually no more than 2),20
whereas the use of LIMA plus long segment
endarterectomy has been proposed to be beneﬁcial
but is complicated by an operative mortality of 3.0 to
4.0% and a perioperative myocardial infarction rate of
4.0%.21 The full-metal jacket technique using DES,
despite being considered relatively safe and effective,
showed on long-term, rates of cardiac death, MI, TLR,
and TVR of 6%, 6%, 27%, and 30%, respectively. The
MACE rate was 15–34% in recent reports with a
deﬁnite and probable stent thrombosis rate of
3–3.6%.21–23
It appears clear that the proposed strategy of
combined third generation DES plus multiple BVS
can be appealing, requiring nothing different than
the usual antiplatelet regimen of multiple DES
implantation. The obvious advantages could be to
leave, in a relatively short time, a virtually na€ıve
artery, maintaining the option of a LIMA implanta-
tion or a further stent procedure in case of new
atherosclerosis onset in the index artery, and to
ensure an optimal results at level of proximal LAD,
which usually included an eventually calciﬁed
bifurcation, at the moment relatively contraindi-
cated for BVS use.24
Table 2. Speciﬁc Data of the LAD Revascularization Procedure and Follow-Up
Pt Indication BVS (d l, mm) FU (Months) Re-Cath Indication Additional Tx
1 ACS 2.5  28/2.5  18 6 Staged PCI RCA PCI RCA (DES)
2 ACS 2.5  28/3.0  18 6 Staged PCI RCA/LCx PCI RCA/LCx(DES)
3 ACS 2.5  28 6 Staged PCI RCA/LCx PCI CDX CX (DES) PCI RCA/LCx(DES)
4 ACS 2.5  28 6 Staged PCI RCA/LCx PCI RCA/LCx(DES)
5 ACS 2.5  28 6 Staged PCI RCA/LCx PCI RCA/LCx
6 ACS 2.5  28/3.0  18 6 Staged PCI RCA PCI RCA
7 ACS 2.5  28/2.5  28 7 Nuclear stress test þ Clinical FU
8 ACS 2.5  28/2.5  28 7 Effort angina —
9 ACS 2.5  28/2.5  28 Clinical FU — —
10 ACS 2.5  28 7 Nuclear stress test þ PCI LCx/RCA
11 ACS 2.5  28/2.5  28 Clinical FU — —
12 ST-el ACS 2.5  28/2.5  28 Clinical FU — —
13 ST-el ACS 2.5  23 6 Staged PCI RCA PCI RCA
14 ACS 2.5þ3.0  28/3.5  23 8 Effort angina None
15 ACS 2.5 28 Clinical FU — —
16 ST-el ACS 2.5 28/3 18/3.5 23 6 Staged PCI RCA PCI RCA
17 ACS 2.5 23 Clinical FU — —
18 ACS 2.5 28 Clinical FU — —
19 ST-el ACS 2.5 28/3 28/3.5 12 6 Staged PCI RCA PCI RCA
20 ACS 2.5 28 Clinical FU — —
21 ACS 2.5 28/3 18 8 Nuclear stress þ —
22 ACS 2.5 28 8 Nuclear stress þ —
23 ACS 2.5 18/3.0 28 Clinical FU — —
D l: diameter length; FU, follow up; LCx, left Circumﬂex coronary artery; PCI, percutaneous coronary interventions; RCA, right coronary
artery. The infarcted vessel was LCx or Obtuse marginal branch.
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As expected, with a relatively short invasive
follow-up period, mainly driven by clinical status
or staged additional procedures, we did not observe
vessel enlargement in the segment treated by BVS:
the angiographic and IVUS parameters remained
substantially unchanged. The time between the
index procedure and the known reabsorption time
of the BVS was too short to allow restoration of the
functional properties of the vessels. In other word
we assessed stented vessels rather than an already
“cured vessels”. However, the invasive follow-up
in half of the patients was useful, as we could
assess the status of the transition zones between the
stents and scaffolds and eventual restenosis or
thrombosis.
An additional lesson learned in our brief experi-
ence in this challenging population, was to ensure
that the procedure is as short as possible in order to
avoid perioperative troponin release and intra-
operative stent or scaffold thrombosis. Repeated
balloon dilation for lesion preparation and stent or
scaffold post-dilation during deployment, heavily
challenge the vessel, so meticulous ACT control
during the procedure, short inﬂation and deﬂation
times and methodically following all procedural
steps, may help in maintaining short procedural
times, thus decreasing the risk of thrombus formation
or complications. Implantation of the BVS ﬁrst and
overexpansion, followed by DES deployment, avoid-
ing difﬁculties in advancing the scaffolds even
through an already well expanded DES, seem
imperative in order to decrease long vessel manipu-
lation and will expedite the procedure.
Limitations. Obviously our study suffers from
several limitations including ﬁrstly the small popula-
tion sample, which also reﬂects the very peculiar
Figure 3. Follow- up at 7 months of the same patient: (central panel) Angiographic follow-up demonstrating vessel patency; IVUS examination
conﬁrming the absence of signiﬁcant restenosis with no gap and no overlapping at both sites of BVS/BVS (B) and BVS/DES (C) transition zones
and throughout the entire LAD from distal (A) to proximal (D). IVUS conﬁrmed the angiographic good results following the AVIO criteria. CSA:
stent cross sectional area; Max diam: maximum diameter.
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anatomical presentation of our patients. Secondly, the
study was conceived as non-randomized: randomiza-
tion 1:1 with a full metal jacket technique, for itself still
debated as standard of treatment in such patients, was
thought not to be ethical because of the young age of
the patients.
Thirdly, a lack of angiographic and IVUS follow-up
for all the patients was clearly evident: for ethical and
legal reasons a policy of submitting patients to
coronary angiography and IVUS examination not-
driven by clinical need was not feasible and perceived
as potentially harmful. Fourthly, we have to
Table 3. Basal, Post-Stent Implantation and Follow-Up Angiographic and IVUS Examination Data in 12 Patients With Available Invasive
Follow-Up
QCA IVUS
Baseline Post-PCI FU Baseline Post-PCI FU
Vessel Segment Ca MLD DS% MLD MLD MLA CSA CSA
LAD D 13/15 (86.6) 2.3  1.2 88.4  1.1 3.6 1.8 3.5  1.4 2.10 0.8 8.14 0.7 8.12  0.5
LAD II 6/15 (40) 1.9  1.4 85.4  3.7 2.8 3.5 2.7  3.1 1.87 0.6 4.7 1.8 4.6  1.5
LAD III 0/15 (0) 0.9  2.2 87.6  5.6 2.5 2.1 2.5  1.9 0.98 0.7 3.8 1.1 3.6  0.8
Ca, calciﬁcation; CSA, stent cross sectional area (mm2); FU, follow-up;MLA,minimal lumen area (mm2);MLD,minimal lumen diameter (mm);
DS%, Diameter stenosis.
Figure 4. Coronary angiography in a 55-year-old male (patient n°6) with non ST-elevation ACS involving LAD as the culprit lesion: (A) long
and diffuse disease of the entire length of the LAD with a heavily diseased and calciﬁed proximal LAD (B) and occlusion of D1. The disease
extended up to the distal LAD (C); immediate result after implantation of Absorb 2.5 28mm, 3.0 18mm and a 3.5 28mm Promus Premier
(D); follow-up at 6 month during staged PCI on RCA demonstrating vessel patency with no angiographic restenosis (E), and no stents
malapposition throughout the length of the vessel (F–H).
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acknowledge the lack of an optical coherence
tomography investigation, which surely would add
information on edge-to-edge technique and scaffold
status: because of ﬁnancial reasons and economic
constraints, the already available IVUS equipment was
preferred: in this sense the use of surrogate endpoints
driven by IVUS ﬁndings is for itself a further
limitation. Finally the assumption that overlapping
between BVS and BVS and DES might be detrimental
in term of risk of thrombosis and/or restenosis remains
speculative since there are not deﬁnitive proof in
current literature.
Conclusions
Taking in account the clinical and anatomical
picture of our study population, and that this represents
the worst scenario for a relatively young patient, the
outcomes appear promising, supporting the claim for
further larger studies. The minimal or no-overlapping
technique was shown not to impact the outcome, being
relatively easy to perform after a short learning curve.
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